(Q48634042)

13 February 2018

title

Anti-CD25 immunotherapy: regulating the regulators (English)

1 reference

13 February 2018

1 reference

John W Rose

1

1 reference

13 February 2018

language of work or name

English

0 references

publication date

1 August 2012

1 reference

13 February 2018

Science Translational Medicine

published in

1 reference

13 February 2018

volume

4

1 reference

13 February 2018

issue

145

1 reference

13 February 2018

page(s)

145fs25

1 reference

13 February 2018

Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004440

Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004440

A humanized antibody that binds to the interleukin 2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004440

Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004440

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004440

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004440

Intrathecal effects of daclizumab treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004440

A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004440

Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004440

CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004440

10.1126/SCITRANSLMED.3004440

21 January 2018

Identifiers

DOI

1 reference

13 February 2018

1 reference

13 February 2018